Pandion Therapeutics Inc. (PAND): Price and Financial Metrics

Pandion Therapeutics Inc. (PAND): $60.05

0.13 (+0.22%)

POWR Rating

Component Grades








Add PAND to Watchlist
Sign Up

Industry: Biotech




#276 of 487

in industry

PAND Price/Volume Stats

Current price $60.05 52-week high $62.90
Prev. close $59.92 52-week low $10.28
Day low $59.95 Volume 241,500
Day high $60.05 Avg. volume 355,921
50-day MA $40.01 Dividend yield N/A
200-day MA $0.00 Market Cap 1.77B

PAND Stock Price Chart Interactive Chart >

Pandion Therapeutics Inc. (PAND) Company Bio

Pandion Therapeutics, Inc. is clinical stage biopharmaceutical company developing novel therapeutics designed to address the unmet needs of patients suffering from autoimmune diseases. The firm develops Therapeutic Autoimmune reguLatOry protein (TALON) drug design and discovery platform. TALON platform employ a modular approach to create a pipeline of product candidates using immunomodulatory effector modules that act at known control nodes within the immune network. The company was founded on December 31, 2018 and is headquartered in Watertown, MA.

PAND Latest News Stream

Event/Time News Detail
Loading, please wait...

PAND Latest Social Stream

Loading social stream, please wait...

View Full PAND Social Stream

Latest PAND News From Around the Web

Below are the latest news stories about Pandion Therapeutics Inc that investors may wish to consider to help them evaluate PAND as an investment opportunity.

SHAREHOLDER ALERT: WeissLaw LLP Reminds FI, SVBI, FRPX, and PAND Shareholders About Its Ongoing Investigations

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

Yahoo | March 18, 2021

Selexis Enters Service Agreement with Pandion Therapeutics to Advance Pandion Antibody

GENEVA--(BUSINESS WIRE)--Selexis SA, a JSR Life Sciences company, announced today that it has signed a service agreement with Pandion Therapeutics, Inc., to advance the development of Pandion’s PT627, a systemically-acting PD-1 agonist antibody for the potential treatment of autoimmune and inflammatory diseases. Under the terms of the agreement, Pandion will utilize Selexis’ proprietary SUREtechnology Platform™ to rapidly develop the research cell banks (RCBs) necessary to advance PT627 to huma

Business Wire | March 16, 2021

INVESTIGATION ALERT: Halper Sadeh LLP Continues to Investigate CUB, PAND, CRHM, JCS; Shareholders Are Encouraged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / March 16, 2021 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:Cubic Corporation (NYSE:CUB) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Veritas Capital and Evergreen Coast Capital Corporation. Under the terms of the merger agreement, Cubic shareholders will receive $70.

Yahoo | March 16, 2021

SHAREHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:

Yahoo | March 16, 2021

Lifshitz Law Firm, P.C. Announces Investigation of MDCA, FPRX, PAND, and PRSP

NEW YORK, NY / ACCESSWIRE / March 14, 2021 /MDC Partners Inc. (NASDAQ:MDCA)Lifshitz Law Firm, P.

Yahoo | March 14, 2021

Read More 'PAND' Stories Here

PAND Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
2023 N/A
2022 N/A
2021 0.00%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!